Windtree Therapeutics Management
Management criteria checks 3/4
Windtree Therapeutics' CEO is Craig Fraser, appointed in Feb 2016, has a tenure of 8.17 years. total yearly compensation is $940.91K, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $3.93K. The average tenure of the management team and the board of directors is 3.9 years and 3.2 years respectively.
Key information
Craig Fraser
Chief executive officer
US$940.9k
Total compensation
| CEO salary percentage | 57.9% |
| CEO tenure | 8.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)
Dec 06Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
Jul 06Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable
Jun 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?
Feb 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$941k | US$545k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$2m | US$480k | -US$68m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$35m |
| Dec 31 2020 | US$770k | US$460k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$32m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$27m |
| Dec 31 2019 | US$1m | US$452k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$43m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$37m |
| Dec 31 2018 | US$5m | US$437k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$9m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$641k | US$425k | -US$25m |
Compensation vs Market: Craig's total compensation ($USD940.91K) is above average for companies of similar size in the US market ($USD681.24K).
Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.
CEO
Craig Fraser (58 yo)
8.2yrs
Tenure
US$940,910
Compensation
Mr. Craig E. Fraser is Chairman of the Board at Windtree Therapeutics, Inc. since June 22, 2023. He has been Chief Executive Officer and President of Windtree Therapeutics, Inc. since February 1, 2016 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.2yrs | US$940.91k | 0.11% $ 3.3k | |
| Senior VP & Chief Medical Officer | 9.5yrs | US$600.01k | 0.0076% $ 236.1 | |
| Senior VP & COO | 4.1yrs | US$1.83m | 0.0040% $ 125.4 | |
| VP, Controller | less than a year | no data | 0.11% $ 3.5k | |
| Vice President of Technical Operations | no data | no data | no data | |
| Executive Director of Clinical Development | 3.8yrs | no data | no data | |
| Head of Operations & Program Management | 3.8yrs | no data | no data |
3.9yrs
Average Tenure
58yo
Average Age
Experienced Management: WINT's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 8.2yrs | US$940.91k | 0.11% $ 3.3k | |
| Independent Director | 5yrs | US$65.34k | 0.0015% $ 48.0 | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | 3.2yrs | US$59.84k | 0.0011% $ 34.0 | |
| Independent Director | 3.2yrs | US$60.34k | 0.0011% $ 34.0 |
3.2yrs
Average Tenure
62yo
Average Age
Experienced Board: WINT's board of directors are considered experienced (3.2 years average tenure).